Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange.

Nature communications - 19 May 2016

Pennington Luke F, Tarchevskaya Svetlana, Brigger Daniel, Sathiyamoorthy Karthik, Graham Michelle T, Nadeau Kari Christine, Eggel Alexander, Jardetzky Theodore S

Abstract excerpt

Omalizumab is a widely used therapeutic anti-IgE antibody. Here we report the crystal structure of the omalizumab-Fab in complex with an IgE-Fc fragment. This structure reveals the mechanism of omalizumab-mediated inhibition of IgE interactions with both high- and low-affinity IgE receptors, and explains why omalizumab selectively binds free IgE. The structure of the complex also provides mechanistic insight into...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Basophils
Share to Cell Line

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Immunoglobulin E

Share to Mutation

Share to Protein Conformation

Share to Receptors, IgE

Source

Open in PubMed Open full text

Identifiers

PMID: 27194387
DOI: 10.1038/ncomms11610
PMCID: PMC4873975

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange.PMID 27194387Read ↗

Structural and Physical Basis for Anti-IgE Therapy.Semantic proximity Read ↗

The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors.Semantic proximity Read ↗

Structural and Functional Insights Into IgE Receptor Interactions and Disruptive InhibitionSemantic proximity Read ↗

Accelerated disassembly of IgE-receptor complexes by a disruptive macromolecular inhibitor.Semantic proximity Read ↗

Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives.Semantic proximity Read ↗

Combined analytical assays for the characterization of drugs binding to human IgE: Applicability to omalizumab-bearing biosimilar candidates assessmentSemantic proximity Read ↗

Influence of effective omalizumab treatment on eosinophils in allergic asthma with comorbiditiesSemantic proximity Read ↗

Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to FcγRIIb.Semantic proximity Read ↗

Comparable actions of omalizumab on mast cells and basophils.Semantic proximity Read ↗

Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha.Semantic proximity Read ↗

FcεRI: A Master Regulator of Mast Cell FunctionsSemantic proximity Read ↗

Clinical Experience with Anti-IgE Monoclonal Antibody (Omalizumab) In Paediatric Severe Allergic Asthma – A Romanian PerspectiveSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.